Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

一种胃泌素释放肽、炎性疾病的技术，应用在脓毒症和急性肺损伤,双相性精神障碍领域

Inactive Publication Date: 2007-12-19
CRISTALIA PROD QUI FARM LTDA
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, without proper treatment, hypomanic patients may turn into severe mania or depression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
  • Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
  • Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0108] I)

[0109] Here, the inventors of the present invention demonstrate the therapeutic potential of the bombesin / GRP antagonist RC-3095 for the treatment of the inflammatory disease rheumatoid arthritis.

[0110] They further demonstrated the therapeutic potential of the bombesin / GRP antagonist RC-3095 for the treatment of two inflammatory diseases, sepsis and acute lung injury. Experiments on the effect of RC-3095 on macrophages revealed that RC-3095 impairs the release of pro-inflammatory cytokines TNF-α and IL-1β by activated macrophages.

[0111] In a well-established model of experimental sepsis, treatment with the bombesin / GRP receptor antagonist RC-3095 attenuated TNF-α and Serum levels of IL-1β and increase survival in inflammatory diseases, especially in "established" sepsis. Furthermore, the bombesin / GRP antagonist RC-3095 was found to reduce lung injury induced by intratracheal instillation of lipopolysaccharide (LPS) in an established acute lung injury (ALI)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of bombesin / gastrin releasing peptide antagonist in the preparation of pharmaceutical composition, said pharmaceutical composition is used for treating inflammatory diseases and immune-mediated inflammatory diseases, especially sepsis , acute lung injury and rheumatoid arthritis and for the treatment or prevention of brain disorders, preferably bipolar disorders, and in particular of different types and / or subtypes of bipolar disorders such as mania, acute mania, Severe mania, hypomania, depression, moderate depression, dysthymia, major depressive disorder, manic and / or depressive episodes, psychotic / psychotic symptoms (e.g., hallucinations, delusions), mixed bipolar states, Bipolar I disorder, bipolar II disorder, and / or rapid cycling bipolar disorder. In particular, specific nonapeptides with antagonist properties against bombesin or bombesin-like peptides such as gastrin-releasing peptide can be used in the treatment of inflammatory and immune-mediated inflammatory diseases and brain disorders .

Description

field of invention [0001] The present invention relates to novel therapeutic strategies for the treatment of inflammatory and immune-mediated inflammatory diseases, particularly sepsis and acute lung injury, by administering bombesin / gastrin releasing peptide antagonists, and Bipolar disorder. Background of the invention [0002] The bombesin / gastrin-releasing peptide (GRP) receptor system (ie, bombesin / gastrin, their receptors and components of receptor-mediated signaling pathways) is known to be involved in several aspects of the CNS Regulation of function (Yamada et al., Mol. Psychiatry 7, 113-117 (2002)), involvement in neuropsychiatric disorders such as schizophrenia (Mellar et al., Peptides 25, 585-588 (2004)) and autism (Ishikawa-Brush et al. , Hum.Mol.Genet.6, 1241-1250 (1997)), involved in the development of cancer (Schwarts-mann, G., Lung Cancer 46, 129 (2004); Szepeshazi et al., Proc.Natl.Acad.Sci.U.S.A.94 , 10913 (1997)), and involvement in the pathogenesis of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/04A61P1/00A61P7/00A61P11/00A61P19/02A61P25/18A61P25/24A61P29/00A61K38/08
CPCA61K38/08A61K38/105A61K38/2207A61P1/00A61P1/04A61P11/00A61P19/02A61P25/00A61P25/08A61P25/18A61P25/20A61P25/24A61P29/00A61P31/04A61P35/00A61P37/02A61P43/00A61P7/00
Inventor G·施瓦特曼R·勒斯勒尔F·戴尔皮佐尔J·L·克韦多F·考普钦斯基
Owner CRISTALIA PROD QUI FARM LTDA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap